GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2007

OGT and Sanger Institute Work on a Test for Prenatal Syndromes

  • Oxford Gene Technology (OGT) and the Wellcome Trust Sanger Institute will develop a single-platform microarray to test for genetic defects in unborn children. The goal of is to develop and validate a microarray to specifically target a number of key prenatal syndromes.

    OGT will design and develop the  60-mer oligonucleotide microarray using its ink jet in situ synthesis platform and work. The company will work with the Sanger Institute’s clinical network to target the most appropriate syndromes.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »